Specialised commissioning

NHS England strikes deal for ground breaking cancer treatment in a new European first

Adult cancer patients in England will receive a new game-changing therapy treatment under the first negotiated deal of its kind struck in Europe, NHS England chief executive Simon Stevens announced today. This is the first time adult NHS patients will have access to CAR-T, and follows a deal NHS England reached last month to make […]

Read more

Thousands of patients to benefit from innovative new treatments on the NHS

Stroke-reducing heart implants and a life changing surgical procedure for children with cerebral palsy are among a host of new treatments that will now be routinely available for thousands of patients on the NHS. The NHS announced its plan to provide the latest innovative treatments for patients, just days after it celebrated its 70th anniversary. Hundreds […]

Read more

As NHS approaches 70 it is time to unleash the potential of innovation to transform patient care, says Simon Stevens

The head of NHS England, Simon Stevens, will today (Tuesday 12 September) set out an ambitious vision for the National Health Service as it approaches its landmark 70th anniversary – calling on health and care leaders to unleash the game changing potential of innovation for both patients and taxpayers. Speaking at Expo conference in Manchester, […]

Read more

NHS patients with rare bone disease to benefit from potentially life-transforming drug due to “first of a kind” agreement between NHS England and the manufacturer

Children and adults with a rare inherited bone disease will be able to access a potentially life-enhancing drug, thanks to an innovative deal between NHS England, NICE and manufacturer Alexion. Hypophosphatasia (HPP) is a rare inherited bone condition that can appear any time from before birth to adulthood. In babies it is often fatal, and […]

Read more

Patients with rare conditions to benefit from new treatments

NHS England has today confirmed that three new specialised treatments will be made available for patients in England. It is estimated that up to 145 people a year will meet the clinical criteria to benefit from the following treatment options being made routinely available to their clinicians with funding from NHS England: Second allogeneic haematopoietic […]

Read more